EUCTR2007-006099-12-DK
Active, not recruiting
Not Applicable
Oral treatment of allergy with a non-pathogenic microorganism: A randomised clinical trial - TSO-01
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Allergic rhinitis
- Sponsor
- Statens Serum Institut
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female, aged \>18 and \<65 years
- •2\.Symptoms of birch and/or grass pollen allergy the last 2 pollen seasons, or more.
- •3\.Forced Expiratory Volume 1 \>70% of expected.
- •4\.Scoring all symptoms of allergic rhinitis \>50 mm on a 100 mm VAS (0\=not bothersome, 10\=worst)
- •5\.Specific IgE class \>2 to birch and/or grass (\>0\.7 kUallergen/l)
- •6\.A positive skin prick test (\>3mm) to birch and/or grass
- •7\.Women must not be pregnant, and women in fertile age must have a negative pregnancy test, not be breastfeeding, and use birth control during the trial unless sterile or post meno\-pausal
- •8\.Prepared to grant authorized persons access to medical records
- •9\.The volunteer is likely to comply with instructions
- •Are the trial subjects under 18? no
Exclusion Criteria
- •1\.Significant asthma
- •2\.Use of systemic steroids during the last 2 months
- •3\.Immune therapy for birch or grass pollen allergy the last 2 years, or more.
- •4\.Planning a travel abroad during the trial period (excluding areas with a similar grass/birch pollen counts when compared with the Copenhagen area)
- •5\.Past or current severe diseases (a history of active hepatitis B or C, cytomegalovirus, herpes simplex, HIV, other kinds of immune deficiency, and cancer)
- •6\.Anti\-helminth treatment within the last 2 weeks (e.g mebendazol)
- •7\.Known or possible hypersensitivity to Trichuris species or compounds made of Trichuris species
- •8\.A past or recent drug abuse
- •9\.Participation in other clinical trials
- •10\.Employed with the Investigator (Pulmonology\- and Allergy Clinic Copenhagen (center of trial)), or the relevant department at the sponsor institution (Department of Epidemiology Research at Statens Serum Institut).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Oral treatment of allergy with a non-pathogenic microorganism: A randomised clinical trialJPRN-UMIN000001070Sponsor's representative: Mads Melbye, Executive Vicepresident, Statens Serum Institut, Dept. Epidemiology Research, Artillerivej 5, DK-2300 Copenhagen, Denmark100
Recruiting
Not Applicable
ow-dose oral immunotherapy for food allergies (buckwheat, fruits, walnuts, cashews, hazelnuts, and macadamia nuts).food allergyJPRN-UMIN000040531ational Hospital Organization Sagamihara National Hospital30
Completed
Not Applicable
Effect of oral immunotherapy with hypoallergenic formula for severe milk allergenic patientssevere milk allergyJPRN-UMIN000013374Fujita Health University30
Recruiting
Not Applicable
Oral immunotherapy with low allergenic egg contains cookies in 0-5 year old patientsegg allergyJPRN-UMIN000040730osaka habikino medical center60
Recruiting
Not Applicable
The effect of oral immunotherapy for food allergyfood allergyJPRN-UMIN000029251Saitama city hospital50